Molecular Biomedicine(国际刊号) 知网目次
- 主管单位:
- 主办单位:
四川省国际医学交流促进会、Springer Nature
- 国际刊号:
2662-8651
- 国内刊号:
- 学科分类:
- 字数:
-
- 有无基金:
- 周期:
国际号刊-年刊
- 特殊属性:
外文期刊
- 电话:
- 邮箱:
molbiomed@med-cens.orgeditorial@molbiomed.org(官网邮箱)
- 复合因子:
0
- 综合因子:
0
- 收录:
知网目次
- 级别:
期刊简介
《Molecular Biomedicine(国际刊号)》期刊已被查看: 次
更新频次
单位占比
一作占比
投稿指南
1、该刊只有国际刊号!
2、投稿方式:在线投稿。
3、官网网址:
https://www.springer.com/journal/43556
(微信公众号信息)
4、投稿系统:https://www.editorialmanager.com/mbmc
5、主办单位官网:https://www.scimea.cn/
(四川省国际医学交流促进会)
6、官网邮箱:molbiomed@med-cens.org(编辑部)
editorial@molbiomed.org(编辑部)
7、官方微信公众号:四川省国际医学交流促进会(scimea)
2022年3月18日星期五
Molecular Biomedicine简介
Molecular Biomedicine 是由全球领先出版商Springer Nature发行的同行评审在线OA期刊(https://www.springer.com/journal/43556),是中国科学院院士魏于全教授主编的又一高水平生物医学期刊。同时,魏院士还创办了Signal Transduction and Targeted Therapy(简称STTT ),2020年影响因子18.187,位于SCI期刊JCR分区Q1区,全球生物化学和分子生物类期刊排名第5、细胞生物学类期刊排名第11。相信Molecular Biomedicine 有院士领队,强大编委团队支持,定是潜力无限,未来可期。
Molecular Biomedicine主编由荷兰格罗宁根大学Arnold J.M. Driessen教授(荷兰皇家科学院院士)和四川大学华西医院生物治疗国家重点实验室魏于全教授(中国科学院院士)担任。编委团队由全球10多个国家的著名科学家构成,其中超过20%为国内外院士,80%以上为国外专家,包括董晨院士、高福院士、韩家淮院士、宋伟宏院士、丁楅森教授、邓宏魁教授等著名专家教授。自开放投稿以来,始终坚持高水平、国际化、严标准的办刊策略,所有刊载内容均经过严格的同行评审,专业高效的编辑团队管理,得到了国内外同行学者的广泛认可。
目前期刊已在线发表文章50余篇,通讯国际背景接近70%,其中包括鲁汶大学Anabelle Decottignies教授、耶鲁大学Darryl T. Martin、荷兰莱顿大学Pieter Velden教授、诺丁汉大学Srinivasan Madhusudan教授、哥伦比亚大学Akiva Mintz教授、宾夕法尼亚大学徐小威教授、北达科他大学吴敏教授、四川大学黄灿华教授、中南大学陶永光、南京大学何农跃教授等全球知名专家学者稿件。
Molecular Biomedicine(简称Mol Biomed )是同行评审的在线发表开放获取 (OA) 期刊,及时出版基于分子角度的生物医学领域的基础研究与临床研究关注,重点关注人类疾病的发展机制、预防、诊断和治疗等方面的研究进展,感兴趣的主题包括表观遗传学、基因组学和蛋白质组学、基因编辑、RNA生物学、信号转导、结构生物学、疾病的早期诊断和生物标记、基因治疗、细胞治疗和免疫治疗、小分子靶向治疗、分子成像、医学人工智能、再生医学等。Molecular Biomedicine 发表论文类型包括综述(Review)、展望(Perspective)、研究论文(Research Article)、致编辑信函(Letter)、研究亮点(Research Highlight)等。Molecular Biomedicine 由衷地感谢期刊作者、审稿人和读者的巨大贡献, Molecular Biomedicine 将不断进步,发表更多高质量的论文,更好地服务于全球的读者和作者。
《Molecular Biomedicine》投稿指南
【官网信息】
Submission guidelines
Instructions for Authors
Article-Processing Charge
Molecular Biomedicine is an Open Access publication and an article-processing charge (APC) is levied on articles that are accepted for publication by the Editors.
The APC for this journal is covered by Sichuan International Medical Exchange & Promotion Association, in 2020-2022.
Article Types
Research
Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more than 8 display items (such as figures or tables).
Research papers should contain an unstructured abstract with up to 250 words. Additional display items will be published online as Supplemental Information.
Review
A review should be a comprehensive synthesis and/or analysis of specific topics. A short Introduction giving the rationale for the review should be followed by sections with appropriate subheadings, followed by a conclusions section at the end. The standard footer headings (Acknowledgements, Contributions, Competing Interests, and Funding) are required. All invited reviews will undergo peer review prior to acceptance.
Review papers should contain an unstructured abstract with up to 250 words, at least 3000 words in length. Review papers should contain around 4-8 figures and tables in total, around 100-500 references.
Letter
Letters provide rapid and concise report of a novel finding that is brief in nature but is of general interest to the field. There should be no more than 10 authors.
No abstract needed for Letter papers. It should include 1200 words max excluding references, figures and tables. A letter should contain, but no more than 1 display item and references are limited to 5.
Research Highlight
Research Highlights discuss the main advances made by the paper as well as putting the finds of the study into the proper context of the field.
A brief stand first of one or two sentences should serve as an abstract. A research highlight paper should include 1000 words max excluding references, figures and tables, and contain, but no more than 1 display item and references are limited to 5. A consensus should be a public statement on professional knowledge in the field of molecular biomedicine, and it is expected to be generally agreed upon as an evidence-based, state-of-the-art knowledge by a representative group of experts in that area.
Consensus
Consensus papers should contain an unstructured Abstract with up to 250 words. Four to Six Keywords representing the main content of the article. The Background section should a concise summary of a search of the existing literature and the issue under discussion. The standard footer headings (Acknowledgements, Contributions, Competing Interests, and Funding) are required.
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Please follow the hyperlink “Submit manuscript” and upload all of your manuscript files following the instructions given on the screen.
Source Files
Please ensure you provide all relevant editable source files at every submission and revision. Failing to submit a complete set of editable source files will result in your article not being considered for review. For your manuscript text please always submit in common word processing formats such as .docx or LaTeX.
……
更多详情:
https://www.springer.com/journal/43556/submission-guidelines
中国全科医学发文选摘
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
《Molecular Biomedicine(国际刊号)》同类生物科学,医卫综论期刊
常见问题
-
哪些期刊可以用来评职称?
1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。
-
你们的服务可以保证文章被发表吗?
期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。
-
请问发表一篇期刊的费用是多少?
期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。
-
如果发表不成功可以退款吗?
如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。
-
请问文章发表需要多长时间?
不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。
-
期刊发表能加急见刊吗?
为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。